Back

Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland

Lemaitre, J. C.; Perez-Saez, J.; Azman, A.; Rinaldo, A.; Fellay, J.

2020-05-08 epidemiology
10.1101/2020.05.04.20090639
Show abstract

Following the rapid dissemination of COVID-19 cases in Switzerland, large-scale non-pharmaceutical interventions (NPIs) were implemented by the cantons and the federal government between February 28 and March 20. Estimates of the impact of these interventions on SARS-CoV-2 transmission are critical for decision making in this and future outbreaks. We here aim to assess the impact of these NPIs on disease transmission by estimating changes in the basic reproduction number (R0) at national and cantonal levels in relation to the timing of these NPIs. We estimate the time-varying R0 nationally and in twelve cantons by fitting a stochastic transmission model explicitly simulating within hospital dynamics. We use individual-level data of >1,000 hospitalized patients in Switzerland and public daily reports of hospitalizations and deaths. We estimate the national R0 was 3.15 (95% CI: 2.13-3.76) at the start of the epidemic. Starting from around March 6, we find a strong reduction in R0 with a 85% median decrease (95% quantile range, QR: 83%-90%) to a value of 0.44 (95% QR: 0.27-0.65) in the period of March 29-April 5. At the cantonal-level R0 decreased over the course of the epidemic between 71% and 94%. We found that reductions in R0 were synchronous with changes in mobility patterns as estimated through smartphone activity, which started before the official implementation of NPIs. We found that most of the reduction of transmission is due to behavioural changes as opposed to natural immunity, the latter accounting for only about 3% of the total reduction in effective transmission. As Switzerland considers relaxing some of the restrictions of social mixing, current estimates of R0 well below one are promising. However most of inferred transmission reduction was due to behaviour change (<3% due to natural immunity buildup), with an estimated 97% (95% QR: 96.6%-97.2%) of the Swiss population still susceptible to SARS-CoV-2 as of April 24. These results warrant a cautious relaxation of social distance practices and close monitoring of changes in both the basic and effective reproduction numbers.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nature Communications
based on 483 papers
Top 5%
12.7%
2
Epidemics
based on 96 papers
Top 0.4%
10.3%
3
Swiss Medical Weekly
based on 12 papers
Top 0.1%
8.4%
4
Scientific Reports
based on 701 papers
Top 23%
7.7%
5
Science
based on 46 papers
Top 0.5%
7.7%
6
PLOS Computational Biology
based on 141 papers
Top 3%
4.8%
50% of probability mass above
7
Proceedings of the National Academy of Sciences
based on 100 papers
Top 3%
3.0%
8
Eurosurveillance
based on 77 papers
Top 2%
3.0%
9
PLOS ONE
based on 1737 papers
Top 79%
2.8%
10
BMC Medicine
based on 155 papers
Top 6%
2.8%
11
Royal Society Open Science
based on 49 papers
Top 2%
2.5%
12
International Journal of Infectious Diseases
based on 115 papers
Top 10%
1.6%
13
Journal of The Royal Society Interface
based on 54 papers
Top 3%
1.3%
14
Emerging Infectious Diseases
based on 84 papers
Top 8%
1.3%
15
Nature
based on 58 papers
Top 8%
1.2%
16
eLife
based on 262 papers
Top 24%
1.2%
17
International Journal of Epidemiology
based on 65 papers
Top 7%
1.2%
18
Nature Medicine
based on 88 papers
Top 14%
0.8%
19
Science Advances
based on 52 papers
Top 5%
0.8%
20
Clinical Infectious Diseases
based on 219 papers
Top 20%
0.8%
21
Infectious Disease Modelling
based on 50 papers
Top 6%
0.8%
22
BMC Public Health
based on 148 papers
Top 22%
0.8%
23
Epidemiology and Infection
based on 80 papers
Top 10%
0.8%
24
The Lancet Infectious Diseases
based on 57 papers
Top 8%
0.7%
25
Frontiers in Physics
based on 11 papers
Top 2%
0.7%
26
Journal of Epidemiology and Community Health
based on 32 papers
Top 4%
0.7%
27
The Journal of Infectious Diseases
based on 137 papers
Top 12%
0.7%
28
Virus Evolution
based on 26 papers
Top 1%
0.7%
29
The Lancet Public Health
based on 20 papers
Top 2%
0.7%
30
BMC Infectious Diseases
based on 110 papers
Top 21%
0.7%